Christopher Missling
Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp, has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work is dedicated to finding potential cures for rare diseases especially for neurodevelopmental diseases, like Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms as well as neurodegenerative diseases. Dr. Missling is working with his team to advance new potential treatments through clinical trials by involving the respective advocacy groups early on. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.
  • LinkedIn - White Circle

The Rare Advocacy Movement (RAM) is a patient advocacy initiative focused on documenting the evolving complex structure and unique dynamics of the rare disease patient advocacy landscape. RAM serves as a Center of Insight (COI) for those interested in participating in collaborative patient advocacy initiatives and working groups within the rare disease industry. The RAM membership is comprised of a network of patient advocacy professionals that have vowed to abide by the established Code of Conduct for Membership.